Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Small cell lung cancer (SCLC) is an aggressive malignancy with few treatment options.
• Neuroendocrine differentiation is a hallmark of SCLC, influencing its behavior.
• Identifying key regulators of this differentiation is crucial for developing new therapies.

Purpose of the Study:

• To identify critical regulators of neuroendocrine differentiation in SCLC.
• To investigate the role of VGF in SCLC progression and its interaction with the tumor microenvironment.
• To explore VGF and monocarboxylate transporter 1 (MCT-1) as therapeutic targets.

Main Methods:

• Identification of VGF as a regulator of neuroendocrine differentiation.
• Analysis of VGF's role in ASCL1 upregulation via a CREB-dependent pathway.
• Investigation of VGF-mediated fibroblast to cancer-associated fibroblast (CAF) transformation.
• Assessment of metabolic coupling between SCLC cells and CAFs.
• Evaluation of a therapeutic strategy targeting VGF and MCT-1 in vitro and in vivo.

Main Results:

• VGF was identified as a critical regulator of neuroendocrine differentiation in SCLC, particularly in ASCL1+ subtypes.
• VGF promotes ASCL1 expression through a CREB-dependent mechanism.
• VGF induces fibroblast to CAF transformation, creating metabolic coupling via lactate exchange.
• Targeting VGF and MCT-1 effectively disrupted neuroendocrine differentiation and metabolic coupling, showing significant efficacy.

Conclusions:

• VGF plays a central role in SCLC neuroendocrine differentiation and tumor microenvironment modulation.
• Targeting VGF and MCT-1 presents a viable therapeutic strategy for advanced SCLC.
• This research provides novel insights into SCLC pathogenesis and potential treatment avenues.